Market Chatter: Organon Courted by Sun Pharmaceutical Industries, Grunenthal, Private Equity

MT Newswires Live04-16 16:57

Organon (OGN) is a potential acquisition target by India's Sun Pharmaceutical Industries, Germany's Grunenthal, and private equity firms, Bloomberg reported Thursday, citing unnamed people familiar with the matter.

The companies are reportedly consulting with advisers on potential binding bids for Organon to be submitted in the coming weeks, the report said.

The New Jersey-based women's healthcare company was spun off from Merck (MRK) in 2021, the report said.

Organon, Sun, and Grunenthal, didn't immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment